back to top
HomeSHARE MARKETMore Than 90% Increase In Profit Of Pharma Company; Price Target From...

More Than 90% Increase In Profit Of Pharma Company; Price Target From 2024 To 2030

Hot Stocks Alert Join

Pharmaceutical company Aurobindo Pharma Ltd (NSE: AUROPHARMA) released the October-December quarter results of the financial year 2024 on February 10. There has been an annual increase of 90.6 percent in consolidated profit, which has reached Rs 936.2 crore. 

The company registered a profit of Rs 491.2 crore in this quarter of last year. The company’s income in the third quarter of FY 2024 was Rs 7,351.7 crore, which is 14.7 percent more than Rs 6,407 crore in the year-ago.

Aurobindo Pharma’s EBITDA rose to Rs 1,601 crore in the third quarter, up from Rs 954.4 crore in the year-ago period. EBITDA margins have reached 21.8 percent, as compared to 14.9 percent during the previous year period.

The company said that US formulation has increased by 28.9 percent to $451 million. Whereas Europe’s formulation has increased by 1.6 percent year on year to reach 193 million euros.

Net Capex At $103 Million

The company’s net capex was US$103 million, which included US$37 million from its bulk drug PLI project.

The total investment for the PLI project till 31 December 2023 is US$ 230 million and the biosimilar product is US$ 305 million. Total R&D expenditure for the quarter is Rs 398 crore.

Stock Performance

On the last trading session, the company’s shares closed at Rs 1,004.75 with a rise of 0.21 percent. The 52-week high of the stock is 1,177.10. The shares of the company have experienced increases of 112.58 percent over the past year.

About Aurobindo Pharma Ltd 

Aurobindo Pharma Limited is an integrated pharmaceutical business in Hyderabad, India.

The company develops, produces, and sells a diverse assortment of generic pharmaceuticals, specialty pharmaceuticals that are branded, as well as active pharmaceutical ingredients across more than 150 countries.

It is involved in the development of an array of oncology-related as well as hormonal treatments.

The company operates 25 packaging and manufacturing facilities that have been approved by top regulatory agencies like USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA. 

The extensive product range of the company includes seven major therapeutic/product areas that include CNS Antiretroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics, and Anti-Allergic with a solid R&D setup.

Fundamental Analysis of Aurobindo Pharma Ltd

Market Cap₹ 58,778 Cr.
Current Price₹ 1,004.75
52-wk High₹ 1,177 
52-wk Low₹ 443
Stock P/E21.0
Book Value₹ 481
Dividend0.30 %
ROCE9.20 %
ROE7.47 %
Face Value₹ 1.00
P/B Value2.09
OPM18.3 %
EPS₹ 47.3
Debt₹ 6,649 Cr.
Debt to Equity0.24

Aurobindo Pharma Share Price Target 2024 To 2030

Year1st Target2nd Target
2024₹1100₹1184
2025₹1200₹1298
2026₹1300₹1500
2027₹1575₹1648
2028₹1755₹1948
2029₹2000₹2100
2030₹2158₹2348
Hot Stocks Alert Join

Aurobindo Pharma Ltd Shareholding Pattern

Promoters Holding
Dec 202251.84%
Mar 202351.84%
June 202351.84%
Sept 202351.84%
Dec 202351.84%
FII Holding
Dec 202222.31%
Mar 202323.03%
June 202324.12%
Sept 202322.45%
Dec 202320.72%
DII Holding
Dec 202214.90%
Mar 202315.09%
June 202315.73%
Sept 202318.29%
Dec 202320.60%
Hot Stocks Alert Join
Public Holding
Dec 202210.96%
Mar 202310.06%
June 20238.31%
Sept 20237.43%
Dec 20236.85%

Aurobindo Pharma Ltd Share: Last 5 Years’ Financial Condition

To better understand how the market is performing, let’s look at the outlook of this share in the previous years. 

However, investors should be aware of the risks and the market conditions before making any investment decision.

Last 5 Years’ Sales:

2019₹ 19,564 Cr
2020₹ 23,099 Cr
2021₹ 24,775 Cr
2022₹ 23,455 Cr
2023₹ 27,895 Cr

Last 5 Years’ Net Profit:

2019₹ 2,364 Cr
2020₹ 2,844 Cr
2021₹ 5,334 Cr
2022₹ 2,647 Cr
2023₹ 2,768 Cr
Hot Stocks Alert Join

Last 5 Years’ Debt-To-Equity Ratio:

20190.49
20200.32
20210.23
20220.1
20230.18

Last 10 Years’ Profit Growth:

10 Years:21%
5 Years:-5%
3 Years:-12%
Current Year:30%

Last 10 years’ Return on Equity (ROE):

10 Years:18%
5 Years:14%
3 Years:12%
Last Year:7%

Sales Growth Over 10 Years:

10 Years:16%
5 Years:9%
3 Years:2%
Current Year:15%

Conclusion

This article is a complete guide about Aurobindo Pharma Ltd Share. This information and forecasts are based on our research, company fundamentals, history, experiences, and technical analyses. 

Also, We have discussed the share’s prospects and growth potential in detail.

This information will help you in your further investment. 

If you are new to our website and want to get all the latest updates related to the stock market, join us on Telegram Group.

If you have any further queries, please comment below. We will be happy to answer all your questions. 

If you like this information, share the article with as many people as possible.

Disclaimer: Dear readers, we’d like to inform you that we are not authorized by SEBI (Securities and Exchange Board of India). The information on this site is only for informational and educational purposes and shouldn’t be considered financial advice or stock recommendations. Also, the share price predictions are completely for reference purposes. The price predictions will only be valid when there are positive signs on the market. Any uncertainty about the company’s future or the current state of the market will not be considered in this study. We are not responsible for any financial loss you might incur through the information on this site. We provide timely updates about the stock market and financial products to help you make better investment choices. Do your research before any investment.

BEST FOR YOU

LEAVE A REPLY

Please enter your comment!
Please enter your name here